Case of ketoacidosis by a sodium-glucose cotransporter 2 inhibitor in a diabetic patient with a low-carbohydrate diet

Journal of Diabetes Investigation

Volumn 6, Issue 5, 2015, Pages 587-590

  Hayami, Tomohide ^a   Kato, Yoshiro ^a   Kamiya, Hideki ^a   Kondo, Masaki ^a   Naito, Ena ^a   Sugiura, Yukako ^a   Kojima, Chika ^a   Sato, Sami ^a   Yamada, Yuichiro ^a   Kasagi, Rina ^a   Ando, Toshihito ^a   Noda, Saeko ^a   Nakai, Hiromi ^a   Takada, Eriko ^a   Asano, Emi ^a   Motegi, Mikio ^a   Watarai, Atsuko ^b   Kato, Koichi ^c   Nakamura, Jiro ^a  

^a AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b CHUBU ROSAI HOSPITAL   (Japan)

^c AICHI GAKUIN UNIVERSITY   (Japan)

Author keywords

Ketoacidosis; Low carbohydrate diet; Sodium glucose cotransporter 2 inhibitor

Indexed keywords

ALBUMIN; C PEPTIDE; GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN GLARGINE; IPRAGLIFLOZIN; LINAGLIPTIN; LIXISENATIDE; METFORMIN; RINGER LACTATE SOLUTION;

ACIDOSIS; ADULT; ARTICLE; CALORIC INTAKE; CASE REPORT; CLINICAL FEATURE; DIABETES MELLITUS; DIET RESTRICTION; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; FAT INTAKE; FEMALE; GLUCOSE INFUSION; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN TREATMENT; INTENSIVE CARE UNIT; KETOACIDOSIS; KETONURIA; LOW CARBOHYDRATE DIET; POLYURIA; PRADER WILLI SYNDROME; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN INTAKE; TACHYPNEA; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 84940594950     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/jdi.12330     Document Type: Article

References (9)

1. Fujita Y, Inagaki N. Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: clinical data and mechanism of action. J Diabetes Investig 2014; 5: 265-275.
2. Bravata DM, Sanders L, Huang J, et al. Efficacy and safety of low-carbohydrate diets: a systematic review. JAMA 2003; 289: 1837-1850.
3. Chen TY, Smith W, Rosenstock JL, et al. A life-threatening complication of Atkins diet. Lancet 2006; 367: 958.
4. Shah P, Isley WL. Ketoacidosis during a low-carbohydrate diet. N Engl J Med 2006; 354: 97-98.
5. Kitabchi AE, Umpierrez GE, Murphy MB, et al. Management of hyperglycemic crises in patients with diabetes. Diabetes Care 2001; 24: 131-153.
6. Tanaka K, Moriya T, Kanamori A, et al. Analysis and a long-term follow up of ketosis-onset Japanese NIDDM patients. Diabetes Res Clin Pract 1999; 44: 137-146.
7. Merovci A, Solis-Herrera C, Daniele G, et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest 2014; 124: 509-514.
8. Seino Y. Luseogliflozin for the treatment of type 2 diabetes. Expert Opin Pharmacother 2014; 15: 2741-2749.
9. Mudaliar S, Henry RR, Boden G, et al. Changes in insulin sensitivity and insulin secretion with the sodium glucose cotransporter 2 inhibitor dapagliflozin. Diabetes Technol Ther 2014; 16: 137-144.